Abstract
Rationale and Design of a Phase II Open-Label, Multicenter Study to Assess the Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Adult Patients with Sickle Cell Disease
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have